• ESP
  • ENG
  • | Contact us
  • The Institute
    • Who we are
    • Mission, vision, values
    • Scientific Team
    • Collaborative agreements
  • Resources
    • Diagnostic Unit
    • Day Care Unit
    • Therapeutic groups
  • Investigation
    • Research Projects
    • Publications
    • Books
  • Training
    • II Day for family caregivers of patients with Alzheimer’s and other dementias
  • Alzheimers
    • The disease
    • Frequently asked questions
    • Legal advice
  • News
  • Donations
  • The Institute
    • Who we are
    • Mission, vision, values
    • Scientific Team
    • Collaborative agreements
  • Resources
    • Diagnostic Unit
    • Day Care Unit
    • Therapeutic groups
  • Investigation
    • Research Projects
    • Publications
    • Books
  • Training
    • II Day for family caregivers of patients with Alzheimer’s and other dementias
  • Alzheimers
    • The disease
    • Frequently asked questions
    • Legal advice
  • News
  • Donations
  • IANEC: committed
    to society
    to offer solutions in the prevention and treatment of
    Alzheimer's disease and other dementias
  • GERALD Project
    We investigate the relationship between the
    presence of functional genetic variants and
    the age of onset and progression of
    Alzheimer's disease
  • IBIDEM Initiative
    We lead IBIDEM, a systematic approach to the
    knowledge of behavioural disorders in
    dementia to contribute to the development of
    new strategies for their diagnosis,
    prevention and treatment
RANGE OF SERVICES

WHAT WE DO

Research

We develop research initiatives that contribute to the prevention and treatment of Alzheimer’s disease and other dementias.

Diagnostic Unit

For anyone who needs an initial diagnosis or a second opinion after a previous evaluation.

Day Care Unit

Personalized attention applying advanced therapies and state-of-the-art technology.

Therapeutic Groups

For relatives and citizens. To learn to care for others as well as take care of yourself.

News

U.S. gives full approval to Lecanemab to treat Alzheimer’s disease and will fund its use

U.S. gives full approval to Lecanemab to treat Alzheimer’s disease and will fund its use

17 July, 2023
Eli Lilly announces positive top-line results from the TRAILBLAZER-ALZ2 trial of donanemab

Eli Lilly announces positive top-line results from the TRAILBLAZER-ALZ2 trial of donanemab

7 June, 2023
SIRPβ1, microglial response and cognitive decline in Alzheimer´s disease

SIRPβ1, microglial response and cognitive decline in Alzheimer´s disease

11 May, 2023
Resources
  • Diagnostic Unit
  • Day Care Unit
  • Therapeutic groups
Contact
info@ianec.es952 21 20 22
Location
C/ Álamos, 17 29012 - Málaga España

For a future in which Alzheimer's is history

Instituto Andaluz de Neurociencia y Jms Consultor. Todos los derechos reservados.